2 results
Approved WMOCompleted
To determine the safety and efficacy of coversin in the treatment of patients with PNH resistant to eculizumab.
Approved WMOCompleted
Primary purpose: study the feasibility of a new treatment option based on biofeedback in people with intellectual disabilities.Secondary purpose: explore effects of treatment for swallowing problems in people with intellectual disabilities.